2016 Fiscal Year Final Research Report
A novel anti-integrin monoclonal antibody that attenuates mouse liver fibrosis: Mechanism of action and therapeutic application
| Project/Area Number |
26293174
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Partial Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Hiroshima University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
茶山 一彰 広島大学, 医歯薬保健学研究院(医), 教授 (00211376)
正木 崇生 広島大学, 大学病院, 教授 (30397913)
仙谷 和弘 広島大学, 医歯薬保健学研究院(医), 講師 (30508164)
|
|---|
| Research Collaborator |
TSUJINO KAZUYUKI カリフォルニア大学, サンフランシスコ校・肺バイオロジーセンター, 博士研究員
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Keywords | fibrosis / antibody drug / integrin / myofibroblast / stellate cell |
|---|
| Outline of Final Research Achievements |
The first integrin α8β1 blocking mAb (Patent 2011-537260) we have generated showed drastic effects on mouse hepatic fibrosis (Grant-in-aid for challenging exploratory research). We have analyzed α8β1 and demonstrated its weak TGF-β activation, expression on activated stellate cells, and induction of myofibroblastic differentiation. In the present study, to develop the mAb into a medical drug, we investigated anti-fibrotic effects on pulmonary and kidney fibrosis of the mAb, α8 expression on human fibrotic livers, anti-fibrotic effect in fibroblast specific α8 KO mice and epitope mapping of the mAb, which confirmed a potency of the mAb as a medical drug.
|
| Free Research Field |
内科学、分子病態学
|
